{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:48:55Z","timestamp":1792057735729,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["FIS2-2023-01290"],"award-info":[{"award-number":["FIS2-2023-01290"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG 2021\u201325920"],"award-info":[{"award-number":["IG 2021\u201325920"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["P20227KXJK"],"award-info":[{"award-number":["P20227KXJK"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-03057-x","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:04:23Z","timestamp":1784091863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IGF2R: a new player in the IGF2 loop sustaining adrenocortical carcinogenesis"],"prefix":"10.1186","volume":"24","author":[{"given":"Emma","family":"Nozza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Di Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genesio","family":"Di Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cassinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mangone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Tamburello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Hantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura-Sophie","family":"Landwehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Di Dalmazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Peverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"3057_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0002-9440(10)63846-1","volume":"162","author":"TJ Giordano","year":"2003","unstructured":"Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, et al. Distinct Transcriptional Profiles of Adrenocortical Tumors Uncovered by DNA Microarray Analysis. Am J Pathol. 2003;162:521\u201331. https:\/\/doi.org\/10.1016\/S0002-9440(10)63846-1.","journal-title":"Am J Pathol"},{"key":"3057_CR2","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1210\/jc.2008-0065","volume":"93","author":"MQ Almeida","year":"2008","unstructured":"Almeida MQ, Fragoso MCBV, Lotfi CFP, Santos MG, Nishi MY, Costa MHS, et al. Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors. J Clin Endocrinol Metab. 2008;93:3524\u201331. https:\/\/doi.org\/10.1210\/jc.2008-0065.","journal-title":"J Clin Endocrinol Metab"},{"key":"3057_CR3","doi-asserted-by":"publisher","unstructured":"Catalano R, Nozza E, Altieri B, Esposito E, Croci GA, Barbieri AM, et al. Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas. Cell Communication Signal BioMed Cent Ltd. 2025;23. https:\/\/doi.org\/10.1186\/s12964-025-02115-0.","DOI":"10.1186\/s12964-025-02115-0"},{"key":"3057_CR4","doi-asserted-by":"publisher","unstructured":"Altieri B, Tirabassi G, Casa S, Della, Ronchi CL, Balercia G, Orio F, Cancer J et al. Wiley-Liss Inc.; 2016. 2785\u201394. https:\/\/doi.org\/10.1002\/ijc.29950.","DOI":"10.1002\/ijc.29950"},{"key":"3057_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12020-019-01869-1","volume":"64","author":"MC De Martino","year":"2019","unstructured":"De Martino MC, van Koetsveld PM, Feelders RA, de Herder WW, Dogan F, Janssen JAMJL, et al. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. Endocr Humana Press Inc. 2019;64:673\u201384. https:\/\/doi.org\/10.1007\/s12020-019-01869-1.","journal-title":"Endocr Humana Press Inc"},{"key":"3057_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1210\/jc.2008-1456","volume":"94","author":"FM Barlaskar","year":"2009","unstructured":"Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metabolism Endocr Soc. 2009;94:204\u201312. https:\/\/doi.org\/10.1210\/jc.2008-1456.","journal-title":"J Clin Endocrinol Metabolism Endocr Soc"},{"key":"3057_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(15)70081-1.","journal-title":"Lancet Oncol"},{"key":"3057_CR8","doi-asserted-by":"publisher","unstructured":"Martin-Kleiner I, Gall Troselj K. Mannose-6-phosphate\/insulin-like growth factor 2 receptor (M6P\/IGF2R) in carcinogenesis. Cancer Lett. Elsevier Ireland Ltd; 2010. pp. 11\u201322. https:\/\/doi.org\/10.1016\/j.canlet.2009.06.036.","DOI":"10.1016\/j.canlet.2009.06.036"},{"key":"3057_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1023\/A:1005959218524","volume":"47","author":"AJ Oates","year":"1998","unstructured":"Oates AJ, Schumaker L, Jenkins S, Pearce A, DaCosta S, Arun B, et al. The mannose 6-phosphate\/insulin-like growth factor 2 receptor (M6P\/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat. 1998;47:269\u201381.","journal-title":"Breast Cancer Res Treat"},{"key":"3057_CR10","doi-asserted-by":"publisher","unstructured":"Brown J, Jones EY, Forbes BE. Keeping IGF-II under control: Lessons from the IGF-II-IGF2R crystal structure. Trends Biochem Sci. 2009;612\u20139. https:\/\/doi.org\/10.1016\/j.tibs.2009.07.003.","DOI":"10.1016\/j.tibs.2009.07.003"},{"key":"3057_CR11","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1016\/S0021-9258(17)39385-7","volume":"260","author":"Y Oka","year":"1985","unstructured":"Oka Y, Rozek LM, Czech MP. Direct Demonstration of Rapid Insulin-like Growth Factor I1 Receptor Internalization and Recycling in Rat Adipocytes. J Biol Chem. 1985;260:9435\u201342.","journal-title":"J Biol Chem"},{"key":"3057_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1530\/eje.0.1440163","volume":"144","author":"S Leboulleux","year":"2001","unstructured":"Leboulleux S, Gaston V, Boulle N, Le Bouc Y, Gicquel C. Loss of heterozgosity at the mannose 6-phosphate\/insulin-like growth factor 2 receptor locus: A frequent but late event in adrenocortical tumorigenesis. Eur J Endocrinol BioScientifica Ltd. 2001;144:163\u20138. https:\/\/doi.org\/10.1530\/eje.0.1440163.","journal-title":"Eur J Endocrinol BioScientifica Ltd"},{"key":"3057_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.surg.2005.09.031","volume":"138","author":"D Vel\u00e1zquez-Fern\u00e1ndez","year":"2005","unstructured":"Vel\u00e1zquez-Fern\u00e1ndez D, Laurell C, Geli J, H\u00f6\u00f6g A, Odeberg J, Kjellman M, et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery. 2005;138:1087\u201394. https:\/\/doi.org\/10.1016\/j.surg.2005.09.031.","journal-title":"Surgery"},{"key":"3057_CR14","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3892\/ijo.2014.2512","volume":"45","author":"JM Ou","year":"2014","unstructured":"Ou JM, Lian WS, Qiu MK, Dai YX, Dong Q, Shen J, et al. Knockdown of IGF2R suppresses proliferation and induces apoptosis in hemangioma cells in vitro and in vivo. Int J Oncol Spandidos Publications. 2014;45:1241\u20139. https:\/\/doi.org\/10.3892\/ijo.2014.2512.","journal-title":"Int J Oncol Spandidos Publications"},{"key":"3057_CR15","doi-asserted-by":"publisher","unstructured":"Takeda T, Komatsu M, Chiwaki F, Komatsuzaki R, Nakamura K, Tsuji K, et al. Upregulation of IGF2R evades lysosomal dysfunction-induced apoptosis of cervical cancer cells via transport of cathepsins. Cell Death Dis Springer Nat. 2019;10. https:\/\/doi.org\/10.1038\/s41419-019-2117-9.","DOI":"10.1038\/s41419-019-2117-9"},{"key":"3057_CR16","doi-asserted-by":"publisher","first-page":"26150","DOI":"10.1074\/jbc.M703276200","volume":"282","author":"HM El-Shewy","year":"2007","unstructured":"El-Shewy HM, Lee MH, Obeid LM, Jaffa AA, Luttrell LM. The insulin-like growth factor type 1 and insulin-like growth factor type 2\/mannose-6-phosphate receptors independently regulate ERK1\/2 activity in HEK293 cells. J Biol Chem. 2007;282:26150\u20137. https:\/\/doi.org\/10.1074\/jbc.M703276200.","journal-title":"J Biol Chem"},{"key":"3057_CR17","doi-asserted-by":"publisher","first-page":"31399","DOI":"10.1074\/jbc.M605339200","volume":"281","author":"HM El-Shewy","year":"2006","unstructured":"El-Shewy HM, Johnson KR, Lee MH, Jaffa AA, Obeid LM, Luttrell LM. Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1\/2 activation by transactivating sphingosine 1-phosphate receptors. J Biol Chem. 2006;281:31399\u2013407. https:\/\/doi.org\/10.1074\/jbc.M605339200.","journal-title":"J Biol Chem"},{"key":"3057_CR18","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1210\/me.2011-0101","volume":"25","author":"HM El-Shewy","year":"2011","unstructured":"El-Shewy HM, Abdel-Samie SA, al Qalam AM, Lee MH, Kitatani K, Anelli V, et al. Phospholipase C and protein kinase C-\u03b2 2 mediate insulin-like growth factor ii-dependent sphingosine kinase 1 activation. Mol Endocrinol. 2011;25:2144\u201356. https:\/\/doi.org\/10.1210\/me.2011-0101.","journal-title":"Mol Endocrinol"},{"key":"3057_CR19","doi-asserted-by":"publisher","unstructured":"Williams JL, Smith C, Hall C, Khaled Z, Maharaj A, Kwong R, et al. Elevated sphingosine-1-phosphate lyase leads to increased metabolism and reduced survival in adrenocortical carcinoma. Eur J Endocrinol BioScientifica Ltd. 2023;188. https:\/\/doi.org\/10.1093\/ejendo\/lvac007.","DOI":"10.1093\/ejendo\/lvac007"},{"key":"3057_CR20","doi-asserted-by":"crossref","unstructured":"Xu Y, Dong B, Huang J, Kong W, Xue W, Zhu Y et al. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. Oncotarget. 2015;7. www.impactjournals.com\/oncotarget","DOI":"10.18632\/oncotarget.6564"},{"key":"3057_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.745092","author":"O Companioni","year":"2021","unstructured":"Companioni O, Mir C, Garcia-Mayea Y, LLeonart ME. Targeting Sphingolipids for Cancer Therapy. Front Oncol Front Media S A. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.745092.","journal-title":"Front Oncol Front Media S A"},{"key":"3057_CR22","doi-asserted-by":"publisher","unstructured":"Gupta P, Taiyab A, Hussain A, Alajmi MF, Islam A, Hassan MI. Targeting the sphingosine kinase\/sphingosine-1-phosphate signaling axis in drug discovery for cancer therapy. Cancers (Basel). MDPI AG; 2021. https:\/\/doi.org\/10.3390\/cancers13081898.","DOI":"10.3390\/cancers13081898"},{"key":"3057_CR23","doi-asserted-by":"publisher","unstructured":"Pitman MR, Costabile M, Pitson SM. Recent advances in the development of sphingosine kinase inhibitors. Cell. Signal. Elsevier Inc.; 2016. pp. 1349\u201363. https:\/\/doi.org\/10.1016\/j.cellsig.2016.06.007.","DOI":"10.1016\/j.cellsig.2016.06.007"},{"key":"3057_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00280-023-04543-6","volume":"92","author":"AC Boulter","year":"2023","unstructured":"Boulter AC, Maurer BJ, Pogue M, Kang MH, Cho H, Knight A, et al. Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies. Cancer Chemother Pharmacol Springer Sci Bus Media Deutschland GmbH. 2023;92:97\u2013105. https:\/\/doi.org\/10.1007\/s00280-023-04543-6.","journal-title":"Cancer Chemother Pharmacol Springer Sci Bus Media Deutschland GmbH"},{"key":"3057_CR25","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-10-2323","volume":"17","author":"MA Dickson","year":"2011","unstructured":"Dickson MA, Carvajal RD, Merrill AH, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011;17:2484\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2323.","journal-title":"Clin Cancer Res"},{"key":"3057_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1530\/EJE-20-1423","volume":"184","author":"LS Landwehr","year":"2021","unstructured":"Landwehr LS, Schreiner J, Appenzeller S, Kircher S, Herterich S, Sbiera S, et al. A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. Eur J Endocrinol BioScientifica Ltd. 2021;184:823\u201335. https:\/\/doi.org\/10.1530\/EJE-20-1423.","journal-title":"Eur J Endocrinol BioScientifica Ltd"},{"key":"3057_CR27","doi-asserted-by":"crossref","unstructured":"Hantel C, Shapiro I, Poli G, Chiapponi C, Bidlingmaier M, Reincke M et al. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation. Oncotarget. 2016;7. www.impactjournals.com\/oncotarget","DOI":"10.18632\/oncotarget.12685"},{"key":"3057_CR28","doi-asserted-by":"publisher","unstructured":"Sigala S, Rossini E, Abate A, Tamburello M, Bornstein SR, Hantel C. An update on adrenocortical cell lines of human origin. Endocrine. Springer; 2022. pp. 432\u20137. https:\/\/doi.org\/10.1007\/s12020-022-03112-w","DOI":"10.1007\/s12020-022-03112-w"},{"key":"3057_CR29","unstructured":"ISO-10993-5-2009. Biological Evaluation of Medical Devices-Part 5: Tests for in vitro cytotoxicity. International Organization for Standardization. Geneva; 2017."},{"key":"3057_CR30","doi-asserted-by":"publisher","unstructured":"Mete O, Erickson LA, Juhlin CC, de Krijger RR, Sasano H, Volante M et al. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr. Pathol. Springer; 2022. pp. 155\u201396. https:\/\/doi.org\/10.1007\/s12022-022-09710-8","DOI":"10.1007\/s12022-022-09710-8"},{"key":"3057_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/106689690401200304","volume":"12","author":"M Bisceglia","year":"2004","unstructured":"Bisceglia M, Ludovico O, Di Mattia A, Ben-Dor D, Sandbank J, Pasquinelli G, et al. Adrenocortical Oncocytic Tumors: Report of 10 Cases and Review of the Literature. Int J Surg Pathol. 2004;12:231\u201343. https:\/\/doi.org\/10.1177\/106689690401200304.","journal-title":"Int J Surg Pathol"},{"key":"3057_CR32","doi-asserted-by":"publisher","unstructured":"Zhang Y, Cao S, Nie J, Yu S, Gao J, Zhang S, et al. SorCS3 suppresses adrenocortical carcinoma progression by enhancing IGF2R-mediated endocytic trafficking and signaling attenuation. J Transl Med BioMed Cent Ltd. 2025;23. https:\/\/doi.org\/10.1186\/s12967-025-07146-2.","DOI":"10.1186\/s12967-025-07146-2"},{"key":"3057_CR33","doi-asserted-by":"publisher","first-page":"12745","DOI":"10.1016\/s0021-9258(18)45269-6","volume":"262","author":"W Kiess","year":"1987","unstructured":"Kiess W, Haskell JF, Lee L, Greenstein LA, Miller BE, Aarons AL, et al. An antibody that blocks insulin-like growth factor (IGF) binding to the type II IGF receptor is neither an agonist nor an inhibitor of IGF-stimulated biologic responses in L6 myoblasts. J Biol Chem. 1987;262:12745\u201351. https:\/\/doi.org\/10.1016\/s0021-9258(18)45269-6.","journal-title":"J Biol Chem"},{"key":"3057_CR34","doi-asserted-by":"crossref","unstructured":"Nishiura T, Karasuno T, Yoshida H, Nakao H, Ogawa M, Horikawa Y et al. Functional Role of Cation-Independent Mannose 6-Phosphate\/Insulin-Like Growth Factor I1 Receptor in Cell Adhesion and Proliferation of a Human Myeloma Cell Line OPM-2. Blood. 1996. http:\/\/ashpublications.org\/blood\/article-pdf\/88\/9\/3546\/623213\/3546.pdf","DOI":"10.1182\/blood.V88.9.3546.bloodjournal8893546"},{"key":"3057_CR35","doi-asserted-by":"publisher","unstructured":"Liu B, Hu Y, Wan L, Wang L, Cheng L, Sun H, et al. Proteomics analysis of cancer tissues identifies IGF2R as a potential therapeutic target in laryngeal carcinoma. Front Endocrinol (Lausanne) Front Media S A. 2022;13. https:\/\/doi.org\/10.3389\/fendo.2022.1031210.","DOI":"10.3389\/fendo.2022.1031210"},{"key":"3057_CR36","doi-asserted-by":"publisher","unstructured":"Li Z, Lou Y, Wei Y, Guan J, Xu M, Chen B, et al. IGF2R as a master regulator of acquired EGFR inhibitor resistance and therapeutic target in non-small cell lung cancer. Int J Biol Macromol Elsevier B V. 2026;363. https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.152219.","DOI":"10.1016\/j.ijbiomac.2026.152219"},{"key":"3057_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.mce.2011.08.003","volume":"348","author":"NC Lucki","year":"2012","unstructured":"Lucki NC, Li D, Sewer MB. Sphingosine-1-phosphate rapidly increases cortisol biosynthesis and the expression of genes involved in cholesterol uptake and transport in H295R adrenocortical cells. Mol Cell Endocrinol. 2012;348:165\u201375. https:\/\/doi.org\/10.1016\/j.mce.2011.08.003.","journal-title":"Mol Cell Endocrinol"},{"key":"3057_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1210\/me.2011-1150","volume":"26","author":"NC Lucki","year":"2012","unstructured":"Lucki NC, Bandyopadhyay S, Wang E, Merrill AH, Sewer MB. Acid ceramidase (ASAH1) is a global regulator of steroidogenic capacity and adrenocortical gene expression. Mol Endocrinol Endocr Soc. 2012;26:228\u201343. https:\/\/doi.org\/10.1210\/me.2011-1150.","journal-title":"Mol Endocrinol Endocr Soc"},{"key":"3057_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/1751-2980.12131","volume":"15","author":"Y Xing","year":"2014","unstructured":"Xing Y, Wang ZH, Ma DH, Han Y. FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1. J Dig Dis Blackwell Publishing. 2014;15:246\u201359. https:\/\/doi.org\/10.1111\/1751-2980.12131.","journal-title":"J Dig Dis Blackwell Publishing"},{"key":"3057_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/FAAT.1995.1056","volume":"25","author":"LB Kedderis","year":"1995","unstructured":"Kedderis LB, Bozigian HP, Kleeman JM, Hall RL, Palmer TE, Harrison SD, et al. Toxicity of the Protein Kinase C Inhibitor Safingol Administered Alone and in Combination with Chemotherapeutic Agents. Fundam Appl Toxicol. 1995;25:201\u201317. https:\/\/doi.org\/10.1006\/FAAT.1995.1056.","journal-title":"Fundam Appl Toxicol"},{"key":"3057_CR41","unstructured":"Schwartz GK, Ward D, Saltz L, Casper ES, Spiess T, Mullen E et al. A Pilot Clinical\/Pharmacological Study of the Protein Kinase C-specific Inhibitor Safingol Alone and in Combination with Doxorubicin. Clin Cancer Res. 1997. http:\/\/aacrjournals.org\/clincancerres\/article-pdf\/3\/4\/537\/2068535\/537.pdf?casa_token=asQnrT2jyHkAAAAA:2TjiguRklpFj8JPkDDE6yNBvqQUBn_90WoxhfNcrD7IFnAs-tgaCXVZO8jYXXeP2I4fcJIk."}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-03057-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:24:25Z","timestamp":1792056265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-03057-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3057"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-03057-x","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico Ethics Committee (Comitato Etico Milano Area 2, protocol code 554_2022bis, date of approval 9 June 2022).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"544"}}